Commentary on Parker and Weir

Parker RA Weir CJ . Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification. Clin Trials 2020; in press.

Tukey JW . The problem of multiple comparisons, dittoed manuscript of 396 pages. Princeton, NJ: Department of Statistics, Princeton University, 1953.

Dmitrienko A Tamhane AC Bretz F . Multiple testing problems in pharmaceutical statistics. Boca Raton, FL: Chapman & Hall/CRC Biostatistics Series, 2010.

International Conference of Harmonisation. Topic E9: statistical principles for clinical trials. 1998, www.ich.org

US Food and Drug Administration. Guidance for industry on multiple endpoints in clinical trials. 2017, www.fda.gov

European Medicines Agency. Guideline on multiplicity issues in clinical trials. 2017, www.ema.europa.eu

International Conference of Harmonisation. Topic E17: general principles for planning and design of multi-regional clinical trials. 2017, www.ich.org

Collignon O Gartner C Haidich AB , et al. Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella and platform trials. Clin Pharmacol Ther 2020; 107(5): 1059–1067.

MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20(10): 725–741.

Lee I-M Cook NR Gaziano M , et al. Vitamin E in the primary prevention of cardiovascular disease and cancer; the women’s health study: a randomized controlled trial. JAMA 2005; 294: 56–65.

Ridker PM Cook NR Lee IM , et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304.

Gerstein HC Yusuf S Holman R , et al. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47(9): 1519–1527.

Bretz F Maurer W Gallo P . Discussion of ‘Some controversial multiple testing problems in regulatory applications’ by HMJ Hung and S-J Wang. J Biopharm Stat 2009; 19(1): 25–34.

Kaplan R Maughan T Crook A , et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013; 31: 4562–4570.

Herbst RS Gandara DR Hirsch FR , et al. Lung master protocol (Lung-MAP) – a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res 2015; 21: 1514–1524.

Racine- Poon A DAmelio A Jr Sverdlov O , et al. OPTIM-ARTS – an adaptive phase II open platform trial design with application to a metastatic melanoma study. Stat Biopharm Res. Epub Ahead of Print 13 May 2020. DOI: 10.1080/19466315.2020.1749722.

Meyer EL Mesenbrink P Dunger-Baldauf C , et al. The evolution of master protocol clinical trial designs – a systematic literature review. Clin Ther 2020; accepted for publication, https://doi.org/10.1016/j.clinthera.2020.05.010.

Stallard N Todd S Parashar D , et al. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Ann Oncol 2019; 30(4): 506–509.